Filing Details
- Accession Number:
- 0000899243-22-021250
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-06-06 19:00:13
- Reporting Period:
- 2022-06-02
- Accepted Time:
- 2022-06-06 19:00:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1680581 | Fulcrum Therapeutics Inc. | FULC | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1577034 | J Robert Gould | C/O Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge MA 02139 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-06-02 | 16,689 | $7.84 | 523,319 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-06-02 | 16,689 | $7.92 | 506,630 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-06-03 | 25,551 | $7.84 | 532,181 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-06-03 | 25,551 | $7.95 | 506,630 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-06-06 | 24,382 | $7.84 | 531,012 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-06-06 | 24,382 | $8.10 | 506,630 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2022-06-02 | 16,689 | $0.00 | 16,689 | $7.84 |
| Common Stock | Stock Option (right to buy) | Disposition | 2022-06-03 | 25,551 | $0.00 | 25,551 | $7.84 |
| Common Stock | Stock Option (right to buy) | Disposition | 2022-06-06 | 24,382 | $0.00 | 24,382 | $7.84 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 207,891 | 2029-01-21 | No | 4 | M | Direct | |
| 182,340 | 2029-01-21 | No | 4 | M | Direct | |
| 157,958 | 2029-01-21 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $7.95, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.08, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.59, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the "2016 Plan") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022.
Billionaire Hedge Funds
